NASD · Healthcare · Medical Devices · USA
Lucid Diagnostics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
Lucid Diagnostics is a cancer prevention medical diagnostics company that offers EsoGuard, a DNA test performed on esophageal cells collected with the EsoCheck device. The test detects esophageal precancer in patients with chronic heartburn through a brief office procedure and is commercialized through physician offices, test centers, and direct-to-consumer channels.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Lucid Diagnostics Inc stock.
Overvalued: intrinsic value $0.02 per share, market price $0.40, margin of safety -1698.6% (as of 2026-11-17).
A 0.9x revenue multiple, discounted for its losses, values the shares at $0.02; the price of $0.40 is 1699% above that value.
8 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
59 more in this industry show a wider margin of safety.
LUCD is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $0.02; the price of $0.40 is 1699% above that value.
$0.02 per share (as of the 2026-11-17 close), against a market price of $0.40. That is a margin of safety of -1698.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.